All In Biotech

Drug Trial Radar · NCT02101268

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib

Last checked: Nov 20, 2026Latest source record: May 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

156

Actual

Start

Jun 19, 2014

Primary completion

Jul 28, 2016

Study completion Apr 25, 2019

Sponsor

Sponsor type
Industry
First posted
Apr 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to determine the efficacy of momelotinib (MMB) versus best available therapy (BAT) in anemic or thrombocytopenic adults with primary myelofibrosis (PMF), or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) who were treated with ruxolitinib as measured by splenic response rate at Week 24 (SRR24). Participants will be randomized to receive either MMB or BAT for 24 weeks during the randomized treatment phase, after which they will be eligible to receive MMB in an extended treatment phase for up to an additional 204 weeks. After discontinuation of study medication, assessments will continue for 12 additional weeks, after which participants will be contacted for survival follow-up approximately every 6 months for up to 5 years from the date of enrollment or until study termination. For those subjects planning to continue treatment with MMB following the end of the study, the End of Treatment, 30-day, 12-Week, and survival follow-up visits are not required.

Conditions

  • Primary Myelofibrosis (PMF)
  • Post-polycythemia Vera (Post-PV)
  • Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Interventions

  • MomelotinibDrug

    Momelotinib tablet administered orally once daily

  • Best Available Therapy (BAT)Drug

    Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Splenic Response Rate at Week 24Time frame: Week 24

Locations

48 sites in 8 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Gainesville, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Kansas City, Kansas

  • Site not named

    Baltimore, Maryland

  • Site not named

    St Louis, Missouri

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    New York, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Houston, Texas

  • Site not named

    Montreal, Canada

  • Site not named

    Toronto, Canada

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    Lille, France

  • Site not named

    Marseille, France

  • Site not named

    Nantes, France

  • Site not named

    Paris, France

  • Site not named

    Pierre-Bénite, France

  • Site not named

    Toulouse, France

  • Site not named

    Villejuif, France

  • Site not named

    Cologne, Germany

  • Site not named

    Dresden, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Mannheim, Germany

  • Site not named

    Ashkelon, Israel

  • Site not named

    Haifa, Israel

  • Site not named

    Jerusalem, Israel

  • Site not named

    Tel Aviv, Israel

  • Site not named

    Bologna, Italy

  • Site not named

    Florence, Italy

  • Site not named

    Genova, Italy

  • Site not named

    Milan, Italy

  • Site not named

    Novara, Italy

  • Site not named

    Roma, Italy

  • Site not named

    Varese, Italy

  • Site not named

    Badalona, Spain

  • Site not named

    Barcelona, Spain

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.